Special Offers
100% Performance Guaranteed
| Description | |
|---|---|
| Catalogue Number | 16-107 |
| Brand Family | Upstate |
| Trade Name |
|
| Description | Anti-PI3 Kinase Antibody, p85 Protein, agarose conjugate, 200 µg |
| Overview | Anti-PI 3-Kinase antibody (06-195) covalently coupled to protein A-agarose by dimethyl-pimelimidate. |
| Product Information | |
|---|---|
| Format | Gel Immobilized |
| Presentation | PBS, pH 7.4, containing 0.05% sodium azide |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-PI3 Kinase Antibody, p85, agarose conjugate detects level of PI3 Kinase & has been published & validated for use in IP. |
| Key Applications |
|
| Application Notes | Suitable for immunoprecipitation and affinity purification. |
| Biological Information | |
|---|---|
| Host | Rabbit |
| Species Reactivity |
|
| Antibody Type | Polyclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | Phosphatidylinositol 3-kinase phosphorylates the inositol ring of phosphatidylinositol at the 3-prime position. The enzyme comprises a 110 kD catalytic subunit and a regulatory subunit of either 85, 55, or 50 kD. This gene encodes the 85 kD regulatory subunit. Phosphatidylinositol 3-kinase plays an important role in the metabolic actions of insulin, and a mutation in this gene has been associated with insulin resistance. Alternative splicing of this gene results in three transcript variants encoding different isoforms. |
| Gene Symbol |
|
| Target Sub-Family | PI3K/PI4K |
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P27986 # Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. SIZE: 724 amino acids; 83598 Da SUBUNIT: Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunits. Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3 (By similarity). Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C- terminus of both proteins and leads to increased production of HIV. Interacts with HCV NS5A. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1. TISSUE SPECIFICITY: Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level). DOMAIN: SwissProt: P27986 The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef. PTM: Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.DISEASE:SwissProt: P27986 # Defects in PIK3R1 are a cause of severe insulin resistance. SIMILARITY: Belongs to the PI3K p85 subunit family. & Contains 1 Rho-GAP domain. & Contains 2 SH2 domains. & Contains 1 SH3 domain. |
| Product Usage Statements | |
|---|---|
| Quality Assurance | routinely evaluated by immunoprecipitating PI 3-Kinase from RIPA lysate of EGF-stimulated human A431 carcinoma cells |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | 1 year at 4°C |
| Packaging Information | |
|---|---|
| Material Size | 200 µg |